Alpha-1 Antitrypsin Deficiency Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The alpha-1 antitrypsin deficiency market reached a value of USD 1.5 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 4.4 Million by 2035, exhibiting a growth rate (CAGR) of 10.02% during 2025-2035.

The alpha-1 antitrypsin deficiency market has been comprehensively analyzed in IMARC's new report titled "Alpha-1 Antitrypsin Deficiency Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Alpha-1 antitrypsin deficiency (AATD) refers to a genetic disorder characterized by decreased levels or malfunctioning of the alpha-1 antitrypsin protein, which leads to a higher risk of developing lung and liver diseases. The most common manifestation is lung disorder, which can include chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, etc. Individuals with AATD may experience various symptoms, such as shortness of breath, wheezing, coughing, recurring respiratory infections, etc. In some cases, the ailment can also affect the liver, leading to liver diseases characterized by jaundice, fatigue, and abdominal swelling. The diagnosis of alpha-1 antitrypsin deficiency typically consists of a combination of clinical evaluation, laboratory investigations, and genetic analysis. Numerous laboratory tests, such as alpha-1 antitrypsin protein level measurement and protease inhibitor activity assays, can provide initial indications of deficiency. A confirmatory diagnosis includes genetic testing to identify mutations in the SERPINA1 gene, which encodes the alpha-1 antitrypsin protein. Additionally, various other procedures, such as lung function tests, imaging studies, liver function tests, etc., may be performed to assess the extent of lung or liver involvement.

The rising cases of genetic mutations that result in the production of abnormal protein variants, thereby leading to an imbalance of protease enzymes in the body, are primarily driving the alpha-1 antitrypsin deficiency market. Apart from this, the widespread adoption of augmentation therapy, which involves regular intravenous infusions of purified alpha-1 antitrypsin protein, to protect the lungs from damage caused by an imbalance of protease enzymes, is acting as another significant growth-inducing factor. Additionally, the increasing utilization of pulmonary rehabilitation programs involving exercises and breathing techniques for improving lung function, developing physical endurance, and optimizing overall respiratory health is also augmenting the market growth. Moreover, several key players are making significant investments in R&D activities to introduce disease-modifying therapies that focus on reducing the accumulation of misfolded alpha-1 antitrypsin protein within cells and enhancing the clearance of abnormal protein aggregates. This, in turn, is creating a positive outlook for the market. Besides this, the emerging popularity of expanded genetic panels since they allow the identification of rare or novel mutations in addition to the commonly screened mutations, thereby improving the accuracy of genetic diagnosis, is expected to drive the alpha-1 antitrypsin deficiency market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the alpha-1 antitrypsin deficiency market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for alpha-1 antitrypsin deficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the alpha-1 antitrypsin deficiency market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the alpha-1 antitrypsin deficiency market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the alpha-1 antitrypsin deficiency market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current alpha-1 antitrypsin deficiency marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the alpha-1 antitrypsin deficiency market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the alpha-1 antitrypsin deficiency across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the alpha-1 antitrypsin deficiency across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of alpha-1 antitrypsin deficiency across the seven major markets?
• What is the number of prevalent cases (2019-2035) of alpha-1 antitrypsin deficiency by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of alpha-1 antitrypsin deficiency by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of alpha-1 antitrypsin deficiency by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with alpha-1 antitrypsin deficiency across the seven major markets?
• What is the size of the alpha-1 antitrypsin deficiency patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend alpha-1 antitrypsin deficiency of?
• What will be the growth rate of patients across the seven major markets?

Alpha-1 Antitrypsin Deficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for alpha-1 antitrypsin deficiency drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the alpha-1 antitrypsin deficiency market?
• What are the key regulatory events related to the alpha-1 antitrypsin deficiency market?
• What is the structure of clinical trial landscape by status related to the alpha-1 antitrypsin deficiency market?
• What is the structure of clinical trial landscape by phase related to the alpha-1 antitrypsin deficiency market?
• What is the structure of clinical trial landscape by route of administration related to the alpha-1 antitrypsin deficiency market?